The report is classified into five parts, as follows:

1. Macro information on China's biopharmaceutical industry

China's macroeconomic environment analysis; China's policies and regulations on biopharmaceutical industry; China's access to WTO and its influence on China's biopharmaceutical industry; biopharmaceutical industrial technology level, developing situation and trends at home and abroad.

2. The global biopharmaceutical market

Current R&D trends of the global biopharmaceutical industry; global biopharmaceutical market analysis before and in 2005, including: market scale, sales status, products and enterprises analysis.

3. In-depth perspectives on China's biopharmaceutical industry and market

Quantitative and qualitative analysis of China's biopharmaceutical production and market sales characteristics before and in 2005; problems existing in China's biopharmaceutical industry; analysis on biological engineering, biological vaccine, diagnosis reagent and IFN markets; the status of China's biopharmaceutical operations;

4. Biotechnology development and market trends

The latest development trends and advanced management systems. Market forecast on China's biopharmaceutical market in 2006, including: factors influencing China's biopharmaceutical industry development in 2006, China's biopharmaceutical market variables in 2006, and future development of China's biopharmaceutical industry. 

5. Investment suggestions

Investment feasibility analysis, risk analysis, profitability analysis and products development suggestions.

2.The political environment of Chin's biopharmaceutical industry in 2006
2.1 China's medical regulatory system analysis
2.1.1 Government control on medical industry 
2.1.2 Establishment of the national medical system
2.1.3 GMP certification
2.1.4 GSP certification for drug enterprises
2.1.5 GAP certification for Chinese traditional medicine 
2.1.6 GCP police for new drug experiments
2.1.7 International GLP accreditation advanced in China
2.1.8 MOH's administrative and regulatory measures to medical industry in 2005 
2.2 China's medical treatment system reform and its influences
2.2.1 Basic urban medical insurance system  
2.2.2 Rural medical treatment system improvements
2.2.3 Commercial medical insurance system establishment and its influences 
2.4 Medicine intellectual property right protections
2.4.1 Fake and patent drugs
2.4.2 WTO related clauses 
2.4.3 The intellectual property right protection of Chinese traditional medicine 
2.5 Medical open-up policy after China's access to WTO
2.5.1 Commitments on medical products after China's access to WTO 
2.5.2 Related policies for foreign investments in medical manufacturing 

3.Technological environment analysis of China's biopharmaceutical industry in 2006
3.1 The global development of basic medical science in 2005 and perspectives on 2006
3.1.1 Global medical research and development in 2005
3.1.2 Analysis of failed cases on global medical research, 2004-2005
3.1.3 Global medical market hotspots forecast in 2006
3.1.4 WHO's 6 drug categories prior to be developed 
3.2 China's medical development
3.2.1 China's basic medical science development
3.2.2 Medical products development in china
3.2.3 Medicine certification in China, 2004-2005
3.2.4 New medical research hotspots in China in 2006

4.China's biopharmaceutical industry investment
4.1 Investment characteristics
4.1.1 Growth analysis 
4.1.2 Profitability analysis 
4.1.3 Investment barriers analysis 
4.1.4 Investment risk analysis 
4.2 Investments in China's Pharmaceuticals industry in 2005
4.2.1 New and under-process projects 
4.2.2 Investment fund sources and allocation 
4.2.3 Investment returns and existing problems 
4.3 Investment forecast in 2006
4.3.1 Investment scale forecast
4.3.2 Investment distribution forecast
4.3.3. Investment return forecast

5.The global biopharmaceutical market in 2005
5.1 The current biopharmaceutical R&D trends
5.2 Global biopharmaceutical industrial characteristics 

6.China's biopharmaceutical industry development

6.1 China's biopharmaceutical industry operations in 2005
6.1.1 Operation 
6.1.2 Market characteristics
6.2 Existing problems

7.Biopharmaceutical products analysis
7.1 Genetic engineering products
7.1.1 Genetic engineering application and medical innovations
7.1.2 Status quo of China¡¯s genetic engineering products
7.1.3 R&D strength survey of China's genetic engineering enterprises
7.1.4 Genetic engineering prospects
7.2 Biological vaccine
7.2.1 China's vaccines market 
7.2.2 Vaccines market potentials
7.3 Biological diagnosis reagent
7.4 Interferon 

8.China's biopharmaceutical enterprises analysis
8.1 Enterprises rank
8.1.1 Sales of the top 10 biopharmaceutical enterprises in 2005
8.1.2 Sales of the top 200 Biopharmaceutical enterprises in 2004 according to NBSC
8.1.3 Profit of the top 200 Biopharmaceutical enterprises in 2004 according to NBSC
8.2 Operations of listed biopharmaceutical enterprises

9.Biological technology analysis
9.1 The development trends of the global biotechnology and industry
9.1.1 American biotechnology industry is reviving  
9.1.2 Constant growth of biopharmaceutical sales in the world
9.1.3 Continued plant area expansion of the transgenic crops 
9.1.4 Systematization and comprehension of biological technology 
9.1.5 Scientists succeeded in SARS breakthrough
9.2 Biotechnology research and industrialization 
9.2.1 America NIH 
9.2.2 Europe 
9.2.3 Japan
9.2.4 Other countries 
9.3 The latest Biotechnology developments

10.Market forecast on China's biopharmaceutical in 2006 
10.1 Analysis of factors influences China¡¯s biopharmaceutical industry development
10.2 China's biopharmaceutical industry development in 2006 and next ten years
10.3 Perspectives on China's biopharmaceutical industry 
10.3.1 Opportunity brought by biopharmaceutical R&D 
10.3.2 Price down and medical market is thereby further expansive
10.3.3 Market forecast 
10.3.4 International trade 

11.Investment suggestion
11.1 Investment blanks
11.2 Investment orientation